DNL.L

Diurnal Group plc
Diurnal Group PLC - Block Admission Application
11th October 2022, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4038C
Diurnal Group PLC
11 October 2022
 

 

Diurnal Group PLC

 

("Diurnal" or the "Company")

 

Block Admission Application

 

Diurnal Group PLC (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that an application has been made to the London Stock Exchange for a block admission of 1,171,533 ordinary shares of 5 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission").

 

The Block Admission relates to Ordinary Shares that will be issued from time to time in connection with the Company's share plans, including satisfying outstanding options already issued under the Diurnal Share Option Scheme 2015, options issued on the same terms as those issued under the Company's long term incentive plan or share options issued in September 2015. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.

 

It is expected that the Block Admission will become effective on or around 13 October 2022. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

 

For further information, please contact:

 

Diurnal Group PLC                                                      020 3727 1000

Richard Bungay, Interim Chief Executive Officer

 

FTI Consulting (Media and Investor Relations) 020 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

 

Panmure Gordon (Nomad and Broker)             020 7886 2500

Freddy Crossley

Emma Earl

Rupert Dearden

 

 

About Diurnal

 

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information please visit: www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSFLFFDIRLILIF ]]>
TwitterFacebookLinkedIn